LOG IN
SIGN UP
MARKET
VKTX
VKTX
Viking Therapeutics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
2.820
-0.070
-2.42%
After Hours: 2.800 -0.02 -0.71% 17:22 07/01 EDT
OPEN
2.880
PREV CLOSE
2.890
HIGH
2.940
LOW
2.720
VOLUME
746.53K
TURNOVER
0
52 WEEK HIGH
7.20
52 WEEK LOW
2.020
MARKET CAP
218.19M
P/E (TTM)
-3.8446
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Monday
During Monday's trading, 1214 companies set new 52-week lows.
Benzinga · 06/13 16:18
Intercept (ICPT) Announces Delay in Meeting With the FDA
Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.
Zacks · 06/07 14:06
One Viking Therapeutics, Inc. (NASDAQ:VKTX) insider upped their stake by 43% in the previous year
Viewing insider transactions for Viking Therapeutics, Inc.'s ( NASDAQ:VKTX ) over the last year, we see that insiders...
Simply Wall St. · 06/06 16:19
Pfizer (PFE) Gets Fast Track Designation for NASH Therapy
Pfizer (PFE) obtains Fast Track designation for its investigational combination therapy - ervogastat and clesacostat for the treatment of NASH.
Zacks · 05/27 17:34
Viking Therapeutics to Present at H.C. Wainwright Global Investment Conference
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will d...
PR Newswire · 05/16 20:05
10 Stocks to Invest in Under $20 According to Michael Castor’s Sio Capital
In this piece, we will take a look at the ten stocks to invest in under $20 according to Sio Capital. To skip the bottom five stocks in this list, head on over to 5 Stocks to Invest In Under $20 According to Michael Castor’s Sio Capital. Sio Capital is a h...
Insider Monkey · 05/11 12:59
Insiders Buy More Than $50M Of 3 Penny Stocks
Gold futures traded lower on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny ...
Benzinga · 05/04 12:51
Insider Buy: Viking Therapeutics
MT Newswires · 05/03 17:48
No Data
Learn about the latest financial forecast of VKTX. Analyze the recent business situations of Viking Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 10 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
40.00%Strong Buy
60.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average VKTX stock price target is 17.56 with a high estimate of 30.00 and a low estimate of 10.00.
Current 2.820
EPS
Actual
Estimate
-0.17-0.13-0.08-0.04
Institutional Holdings
Institutions: 221
Institutional Holdings: 37.54M
% Owned: 48.51%
Shares Outstanding: 77.37M
TypeInstitutionsShares
Increased
45
6.36M
New
18
622.22K
Decreased
34
11.50M
Sold Out
19
654.77K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Non-Executive Chairman/Independent Director
Lawson Macartney
President/Chief Executive Officer/Director
Brian Lian
Chief Financial Officer/IR Contact Officer
Greg Zante
Chief Operating Officer
Marianne Mancini
Director
Matthew Foehr
Independent Director
S. Kathy Rouan
Independent Director
Charles Rowland
Independent Director
J. Matthew Singleton
No Data
No Data
About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for metabolic and endocrine disorders. The Company's lead clinical program's drug candidate, VK2809, is an orally available, tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß). The Company is conducting VOYAGE study, a phase II b clinical trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH). It is also developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRß for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is engaged in a phase I b clinical trial of VK0214 in patients with X-ALD. Its other clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator (SARM).
Webull offers kinds of Viking Therapeutics Inc stock information, including NASDAQ:VKTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VKTX stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading VKTX stock methods without spending real money on the virtual paper trading platform.